Onychomycosis accounts for one third of fungal skin infections. Because only about one half of nail dystrophies are caused by fungus, the diagnosis should be confirmed by potassium hydroxide preparation, culture or histology before treatment is started. Newer, more effective antifungal agents have made treating onychomycosis easier. Terbinafine and itraconazole are the therapeutic agents of choice. Although the U.S. Food and Drug Administration has not labeled fluconazole for the treatment of onychomycosis, early efficacy data are promising. Continuous oral terbinafine therapy is most effective against dermatophytes, which are responsible for the majority of onychomycosis cases. Intermittent pulse dosing with itraconazole is as safe and effective as short-term continuous therapy but more economical and convenient. With careful monitoring, patients treated with the newer antifungal agents have a good chance of achieving relief from onychomycosis and its complications.
Onychomycosis: A Review of New and Emerging Topical and Device
Treatment course in a 64-year-old man with total dystrophic
ToeFX (@toe_fx) / X
New Oral Antifungals for Treating Onychomycosis
Onychomycosis: Current Trends in Diagnosis and Treatment
Onychomycosis: Understanding, Prevention, and Treatment
JoF, Free Full-Text
Onychomycosis (Fungal Infection) Symptoms - North Toronto Laser
Onychomycosis - Fungal Infection of the Nails
Onychomycosis, Nail Infection
Onychomycosis Treatment Breakthrough